BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Pfizer will end development of weight-loss pill over fears about its impact to the liver - The drugmaker said the patient’s injury ‘resolved’ after they stopped taking the drug ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief ...

Pfizer has officially ended its development of the experimental weight-loss pill, danuglipron, after a potential drug-induced liver injury was reported during a clinical trial. This decision comes as ...